ARCHIVES

ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer

September 24, 1999

NCI Advisory Group, Other Cancer Meetings

November 26, 1976

Clinical Trials Approved By NCI CTEP Last Month

July 29, 2011

FDA Approves DNA Test For Two Types of HPV

March 27, 2009

ASCO Supports Tobacco Tax Increase

March 7, 2003

In Brief: NCFA Offers Grants For Research On Impact Of DRGs; ACCC Leaders Dispute HCFA Chief

March 8, 1985